XML 250 R173.htm IDEA: XBRL DOCUMENT v3.26.1
List of subsidiaries (Details)
12 Months Ended
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2025
HKD ($)
Dec. 31, 2025
GBP (£)
Dec. 31, 2025
TWD ($)
Disclosure of subsidiaries [line items]          
Issued and fully paid share capital $ 25,000 $ 19,000      
Prenetics Limited          
Disclosure of subsidiaries [line items]          
Issued and fully paid share capital     $ 415,276,716    
Directly 0.00% 0.00%      
Indirectly 100.00% 100.00%      
Europa Partners Holdings, LLC (note 33)          
Disclosure of subsidiaries [line items]          
Issued and fully paid share capital | £       £ 11.00  
Directly 0.00% 0.00%      
Indirectly 100.00% 100.00%      
IM8 Group Holding Company          
Disclosure of subsidiaries [line items]          
Issued and fully paid share capital $ 1        
Directly 100.00% 100.00%      
Indirectly 0.00% 0.00%      
IM8 (US) LLC          
Disclosure of subsidiaries [line items]          
Directly 100.00% 100.00%      
Indirectly 0.00% 0.00%      
IM8 Limited          
Disclosure of subsidiaries [line items]          
Issued and fully paid share capital     1    
Directly 100.00% 100.00%      
Indirectly 0.00% 0.00%      
ACT Genomics Holdings Company Limited          
Disclosure of subsidiaries [line items]          
Issued and fully paid share capital $ 16,713        
Directly 0.00% 73.27%      
Indirectly 0.00% 0.00%      
ACT Genomics Co., Ltd.          
Disclosure of subsidiaries [line items]          
Issued and fully paid share capital         $ 455,080,000
Directly 0.00% 0.00%      
Indirectly 0.00% 73.21%      
ACT Genomics (Hong Kong) Limited          
Disclosure of subsidiaries [line items]          
Issued and fully paid share capital     775,000    
Directly 0.00% 0.00%      
Indirectly 0.00% 73.27%      
Sanomics Limited          
Disclosure of subsidiaries [line items]          
Issued and fully paid share capital     $ 500,000    
Directly 0.00% 0.00%      
Indirectly 0.00% 73.27%      
MC Diagnostics Limited          
Disclosure of subsidiaries [line items]          
Issued and fully paid share capital | £       £ 1,164  
Directly 0.00% 0.00%      
Indirectly 0.00% 73.27%